Actos Attorneys of Williams Kherkher Discuss Reports of Declining Actos Sales

(LegalLaw247.com, November 15, 2011 ) Houston, TX -- The Wall Street Journal recently reported that Takeda Pharmaceutical Company, the creator of Actos, experienced a decrease in profit due to lower-than-average Actos sales. The Type 2 diabetes drug has been under investigation for possible links to serious health complications such as bladder cancer. The discovery of this potential connection is thought to have an impact on the drop in sales.

The Food and Drug Administration is continuing to review data from their study and has already published several
 



warnings regarding Actos use.

Takeda Pharmaceutical Company is one of the largest pharmaceutical companies in Japan and has offices in many countries including the United States. The Wall Street Journal reported that profit was down 4.8% from the previous year and year end projections have changed from 250 billion to 170 billion.

According to http://www.pharmatimes.com, Actos was previously the companys highest selling drug, but sales have noticeably declined after the recent warnings in the United States and Europe.

About Williams Kherkher

Williams Kherkher is a mass-tort law firm based in Houston, Texas, offering legal assistance to clients nationwide. The firm handles a variety of cases, including those involving personal injury law, mesothelioma, and defective pharmaceuticals. For more information about Actos lawsuit options, clinical trials, and your rights as a victim, visit the website of the Actos attorneys at http://www.actoslawsuitcounsel.com.

Contact:
Williams Kherkher
8441 Gulf Freeway, Suite 600
Houston, TX. 77017
800-761-3187

Press Release Courtesy of Online PR Media: http://bit.ly/vMDNZN


Stafford Burns
800-641-9810
mail@williamskherkher.com

Source: EmailWire.Com
Subscribe to LegalLaw247.Com Newsletter

Leave a Reply

Your email address will not be published. Required fields are marked *

*


*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>